Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.31p on 24-10-2025 at 18:20:08
Change -0.005p -1.59%
Buy 0.32p
Sell 0.30p
Last Trade: Buy 300,000.00 at 0.3135p
Day's Volume: 23,261,271
Last Close: 0.31p
Open: 0.315p
ISIN: GB00BYW79Y38
Day's Range 0.31p - 0.315p
52wk Range: 0.04p - 0.36p
Market Capitalisation: £5.26m
VWAP: 0.310884p
Shares in Issue: 1.70b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 300,000 0.3135p Ordinary
16:29:54 - 24-Oct-25
Buy* 46,640 0.32p Ordinary
16:26:26 - 24-Oct-25
Sell* 400,000 0.303p Ordinary
16:25:27 - 24-Oct-25
Buy* 81,559 0.3135p Ordinary
16:14:08 - 24-Oct-25
Sell* 300,000 0.3022p Ordinary
16:08:08 - 24-Oct-25
Sell* 500,000 0.3075p Ordinary
16:05:39 - 24-Oct-25
Buy* 500,000 0.3166p Ordinary
16:02:59 - 24-Oct-25
Buy* 250,000 0.316p Ordinary
16:01:55 - 24-Oct-25
Buy* 250,000 0.316p Ordinary
16:01:11 - 24-Oct-25
Buy* 77,317 0.3166p Ordinary
15:48:37 - 24-Oct-25
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
24th Oct 2025 (Fri) 0.315 0.315 0.31 0.31 23,261,271
23rd Oct 2025 (Thu) 0.305 0.335 0.305 0.315 46,364,432
22nd Oct 2025 (Wed) 0.265 0.32 0.265 0.305 55,731,677
21st Oct 2025 (Tue) 0.29 0.29 0.255 0.265 38,548,741
20th Oct 2025 (Mon) 0.285 0.29 0.265 0.265 25,251,853
17th Oct 2025 (Fri) 0.285 0.285 0.26 0.285 40,775,714
16th Oct 2025 (Thu) 0.30 0.286 0.286 0.286 58,071,614
15th Oct 2025 (Wed) 0.265 0.335 0.265 0.30 105,827,787
14th Oct 2025 (Tue) 0.23 0.285 0.23 0.26 60,850,575
13th Oct 2025 (Mon) 0.265 0.265 0.225 0.23 30,665,977
10th Oct 2025 (Fri) 0.28 0.28 0.265 0.265 34,897,692
9th Oct 2025 (Thu) 0.265 0.31 0.265 0.28 63,440,135
8th Oct 2025 (Wed) 0.23 0.305 0.22 0.27 101,794,852
7th Oct 2025 (Tue) 0.195 0.23 0.175 0.23 111,090,950
6th Oct 2025 (Mon) 0.20 0.23 0.19 0.195 87,360,448
3rd Oct 2025 (Fri) 0.24 0.24 0.24 0.24 103,229,334
2nd Oct 2025 (Thu) 0.30 0.36 0.22 0.235 290,314,324
1st Oct 2025 (Wed) 0.231 0.36 0.231 0.30 303,126,410
30th Sep 2025 (Tue) 0.19 0.275 0.19 0.235 251,489,218
29th Sep 2025 (Mon) 0.145 0.2075 0.145 0.19 245,025,163
26th Sep 2025 (Fri) 0.1175 0.165 0.1175 0.145 154,534,245
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
10th Oct 2025 7:00 am RNS Change of Auditor
25th Sep 2025 7:00 am RNS-R European Respiratory Society Congress Attendance
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
22nd May 2025 7:00 am RNS £210,000 Placing
19th May 2025 7:00 am RNS-R Attendance at American Thoracic Society Congress
2nd May 2025 7:00 am RNS Half-year Report
30th Apr 2025 7:00 am RNS Confirmation of European Orphan Drug Designation
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

Nuformix finds positive data for NXP002 in lung fibrosis study

9th Apr 2025 16:29

(Alliance News) - Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed "positive" results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. Read More

UK shareholder meetings calendar - next 7 days

13th Mar 2025 14:41

Read More

See more Nuformix news
FTSE 100 Latest
Value9,645.62
Change67.05

Login to your account

Forgot Password?

Not Registered